UNSPSC 51112012: Afatinib

This classification denotes a quinazoline and antineoplastic agent and tyrosine kinase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 41UD74L59M. European Medicines Agency schedules Afatinib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32268. As of Q4 2014, AFATINIB remains the US FDA Preferred Term for this commodity. Afatinib bears US NLM identifiers UMLS ID C1879772 and NCI Concept Code C66940. SMILES: CN(C)C/C=C/C(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)O[C@H]4CCOC4.

UNSPSC 51112012 Afatinib is a Commodity code tracking a specific pharmaceutical active ingredient used in state and local government procurement frameworks, though recent solicitation activity under this code reflects broader generic multi-source pharmaceutical contracting rather than the drug by name alone. State and local governments procure afatinib and related generic pharmaceuticals through cooperative purchasing agreements to stock inventories across institutional healthcare facilities, correctional systems, and public health programs. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, actively solicits manufacturers and distributors of generic pharmaceuticals including afatinib formulations to supply participating state and local facilities across multiple states including Oregon. Issuing bodies under this code include state procurement offices managing cooperative purchasing vehicles and the state and local healthcare systems and facilities that consume the drugs through those agreements. MMCAP structures these procurements to require vendors to maintain relationships with authorized pharmaceutical wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC), certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, and supply products meeting FDA requirements with minimum shelf-life and expiration guarantees.

MMCAP's January 2026 RFP for generic multi-source pharmaceuticals and OTC products, with a March 26, 2026 response deadline, represents the most recent state-local activity under this code. The cooperative purchasing vehicle spans Minnesota and Oregon with potential participation from additional member states. Evaluation weights pricing competitiveness at 75 percent, with administrative compliance, EDI capability, and pricing format flexibility accounting for the remainder. Contract terms run two years for new vendors with optional renewals at MMCAP's discretion, and incumbent vendors' agreements extend through June 30, 2028. Vendors must carry $5,000,000 commercial general liability insurance, $2,000,000 network security and privacy liability, and $2,000,000 professional liability coverage. The solicitation imposes performance penalties of $200 to $1,500 per violation and reserves the right to make sole, dual, or multi-awards based on therapeutic need and product availability. Specific award values are not disclosed, though vendors should budget for a 3 percent administrative fee on all contract purchases.